Emerging · Research guide

NMN and NR for dogs: does raising NAD+ actually improve ageing?

NAD+ biology is important. The evidence for supplementing its precursors needs to be separated into exposure, biomarkers, function and clinical benefit.

The takeaway

Nara’s take.

NAD+ precursors are plausible research candidates, but 'raises NAD+' is not the same as 'helps your dog live better or longer'. Dog studies exist; their results do not yet establish a routine healthy-ageing regimen.

How it may work

Why NAD+ attracts so much attention

NAD+ participates in energy metabolism and cellular processes involved in repair and stress responses. NMN and NR are compounds used in pathways that can replenish the NAD pool.

The tempting leap is to assume that more substrate always improves the whole system. But availability, tissue context and the reason a pathway has changed all matter. A rise in a blood or tissue measure cannot by itself establish that a dog has been biologically rejuvenated.

Sources: [1], [2], [3]

What the research shows

What the canine evidence reaches

Canine NMN research includes short-term toxicology and an ageing-related intervention study examining inflammatory biology. The latter compared treated dogs before and after intervention without a concurrent untreated comparison, which limits causal interpretation. These provide direct dog exposure or biomarker information, not a demonstration of preserved mobility or lifespan.

A separate senior-dog trial reported improved owner-assessed cognition with a senolytic and NAD-precursor combination, while objective cognitive and activity outcomes were not significantly improved. Because several components were given together, the result cannot be attributed to NMN, NR or NAD elevation alone.

Sources: [1], [2], [4]

What the research shows

Human results should remain labelled as human results

Human trials include an NMN study of muscle insulin sensitivity in prediabetic women and an NR trial of walking performance in people with peripheral artery disease. These are specific populations and outcomes, not general proof of anti-ageing efficacy.

Nara finds them useful for generating questions. They cannot supply an equivalent dog dose or establish that a well-fed, active dog has a deficiency that needs correction. NMN and NR also should not be treated as identical merely because both relate to NAD+ metabolism.

Sources: [5], [3]

Nara's practical guidance

What this means for your dog

This remains a research-led decision rather than a standard supplement recommendation. Short toxicology studies cannot resolve years of exposure, disease interactions or the quality of a particular consumer product. A proprietary blend makes attribution harder still.

Nara would prioritize a defined objective and a clear record over chasing a higher biomarker number. There is no established monitoring target that proves a healthy dog is benefiting, and recurring cost does not become good value because the pathway is important. Replicated canine functional outcomes with an isolated, characterized precursor would substantially strengthen the case.

Evidence informing this guidance: [1], [2], [4]

Follow the evidence

Sources and review notes.

Primary studies, clinical guidance and explicitly labelled sponsor disclosures. A mechanism, an observational association and a treatment result are different kinds of evidence.

Editorial research update: 2026-09-24. These guides build on Nara’s existing source records and a fresh check of accessible primary abstracts, full texts and official pages. This is not an exhaustive systematic review or a new independent clinical review. The evidence assessment retains its own date and status. Practical examples are Nara’s interpretation, not validated treatment protocols.

[1] 2020 · Mouse and Beagle dog · Subacute oral toxicity study
Subacute Toxicity Study of Nicotinamide Mononucleotide via Oral Administration
You Y; Gao Y; Wang H; Li J; Zhang X; Zhu Z; Liu N. Frontiers in Pharmacology.
10.3389/fphar.2020.604404
Direct canine NMN safety evidence; does not establish efficacy and included laboratory changes relevant to chronic-safety uncertainty.
[2] 2024 · Dog · Canine aging transcriptomic and intervention study
Transcriptomic and intervention evidence reveals domestic dogs as a promising model for anti-inflammatory investigation
Zeng M; Zhou T; Li Z et al.. Aging Cell.
10.1111/acel.14127
Provides direct canine NMN-related inflammatory biomarker evidence but not proof of functional healthy-aging benefit.
[3] 2021 · Human · Randomized placebo-controlled intervention trial
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Yoshino M et al.. Science.
10.1126/science.abe9985
Important human NMN metabolic efficacy evidence, but population- and endpoint-specific and not evidence of canine healthspan or lifespan.
[4] 2024 · Dog · Randomized controlled senior-dog combination trial
A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination
Simon KE; Russell K; Mondino A et al.. Scientific Reports.
10.1038/s41598-024-63031-w
Relevant adjacent canine evidence, but the proprietary precursor plus senolytic design prevents attribution to NMN, NR or NAD+ elevation alone.
[5] 2024 · Human · Randomized double-blind clinical trial
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
McDermott MM; Martens CR; Domanchuk KJ et al.. Nature Communications.
10.1038/s41467-024-49092-5
Preliminary human functional evidence for NR using 6-minute walking performance; confirmation was explicitly considered necessary.

Keep reading

Connected questions.

Senolytics

Clearing senescent cells — a strong mechanism with thin canine data.

Urolithin A

A gut-derived postbiotic studied for mitophagy and muscle function.

Biomarker tracking

Baseline and trend bloodwork as an early-detection tool.

Open Nara’s evidence assessment

The guide above explains the topic. This separate record preserves the accepted claim, confidence, limitations and safety context. Publishing an article does not upgrade the science or turn an experimental intervention into a recommendation.

Nara’s evidence view

Research watchlist

PreliminaryCanine biomarkersLow confidence

The claim we’re evaluating

NMN or NR supplementation improves healthy-aging functional outcomes or lifespan in dogs.

Nara’s interpretation

NAD+ biology is compelling, but increasing NAD+ or changing NAD-related biomarkers does not by itself demonstrate better healthspan or lifespan. NMN has limited direct canine intervention evidence involving short-term safety and inflammatory biomarkers, whereas convincing isolated NR outcome evidence in dogs was not identified. Human NMN and NR trials make the pathway scientifically credible enough to follow, but Nara should not present either precursor as a proven canine anti-aging intervention.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

How we reached this view

What the evidence shows

NMN and NR need to remain separate. For NMN, a short-term oral toxicity study in Beagles provides direct canine safety information and reported modest changes including creatinine and uric acid at the studied exposure, while a 2024 aging-focused canine investigation reported changes in inflammatory biomarkers after NMN administration; these data do not establish functional benefit. No verified isolated canine NR efficacy trial was identified through the cutoff. A 2024 senior-dog randomized trial of a proprietary NAD+ precursor combined with a senolytic reported a greater owner-assessed cognitive signal in the full-intervention group, but objective cognitive and activity testing did not establish corresponding improvement and the design cannot attribute any effect to NMN, NR or NAD+ elevation. Human NMN trials demonstrate NAD-related biological effects and some population-specific metabolic or functional signals; NR has also shown a preliminary walking-performance benefit in peripheral artery disease. None demonstrates canine lifespan extension, and biomarker elevation of NAD+ is not itself a health outcome.

Important limitations

NMN and NR are distinct interventions and cannot inherit one another's efficacy evidence.
The direct canine NMN evidence is predominantly safety and biomarker evidence rather than physical, cognitive, healthspan or lifespan outcomes.
No convincing isolated canine NR functional-outcome trial was identified through the cutoff.
The senior-dog combination trial used a proprietary NAD+ precursor together with a senolytic, preventing attribution of effects to the NAD+ precursor or to NMN or NR specifically.
In the combination trial, owner-assessed cognitive change and objective testing did not provide a uniformly concordant efficacy signal.
Human trials involve specific populations and outcomes and cannot establish benefit in healthy or aging dogs.
Raising NAD+ is a pharmacodynamic or biochemical effect, not evidence by itself of improved healthspan or lifespan.

What would change Nara’s view

What would strengthen our view

Separate randomized canine trials of chemically defined NMN and NR measuring prespecified physical, cognitive or clinical outcomes.
Demonstration that any canine NAD+ increase mediates a reproducible functional benefit rather than simply accompanying it.
Independent replication across laboratories and diverse pet-dog populations.
Longer canine follow-up capable of assessing durability and clinically meaningful safety.

What could weaken our view

Adequately powered canine trials showing increased NAD-related biomarkers without meaningful functional improvement.
Replicated human or canine evidence showing that biomarker restoration does not translate into clinically useful outcomes.
Emergence of meaningful chronic safety signals for NMN or NR.

What could change our position

Replicated canine functional benefits from a defined NMN or NR intervention with acceptable safety could justify a subclaim-specific move toward reasonable_to_consider.
Repeated negative efficacy trials despite verified target engagement could move the relevant precursor to not_currently_supported for healthy-aging claims.
A clinically meaningful precursor-specific safety signal could justify potential_concern.

Safety and clinical context

The available canine NMN toxicity study is short-term and should not be treated as chronic-use clearance.
Observed renal-related laboratory changes in the high-exposure NMN experiment warrant distinction from claims of demonstrated toxicity or clinical kidney disease.
Safety and efficacy of an undisclosed proprietary NAD+ precursor cannot be generalized automatically to NMN or NR.

Evidence record

Nara position: Research watchlist
Evidence maturity: Preliminary
Most direct relevant evidence: Canine biomarkers
Overall confidence: Low confidence
Evidence reviewed through: 2026-08-12
Assessment date: 2026-08-12
Review status: Initial Nara internal evidence assessment
Framework: Nara Evidence Framework v1.0

How Nara evaluates science

Anchor sources

Subacute Toxicity Study of Nicotinamide Mononucleotide via Oral Administration

Frontiers in Pharmacology · 2020 · Mouse and Beagle dog

Subacute oral toxicity study

Direct canine NMN safety evidence; does not establish efficacy and included laboratory changes relevant to chronic-safety uncertainty.

10.3389/fphar.2020.604404

Transcriptomic and intervention evidence reveals domestic dogs as a promising model for anti-inflammatory investigation

Aging Cell · 2024 · Dog

Canine aging transcriptomic and intervention study

Provides direct canine NMN-related inflammatory biomarker evidence but not proof of functional healthy-aging benefit.

10.1111/acel.14127

A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination

Scientific Reports · 2024 · Dog

Randomized controlled senior-dog combination trial

Relevant adjacent canine evidence, but the proprietary precursor plus senolytic design prevents attribution to NMN, NR or NAD+ elevation alone.

10.1038/s41598-024-63031-w

Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial

Nature Communications · 2024 · Human

Randomized double-blind clinical trial

Preliminary human functional evidence for NR using 6-minute walking performance; confirmation was explicitly considered necessary.

10.1038/s41467-024-49092-5

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Science · 2021 · Human

Randomized placebo-controlled intervention trial

Important human NMN metabolic efficacy evidence, but population- and endpoint-specific and not evidence of canine healthspan or lifespan.

10.1126/science.abe9985

Your dog’s context

Bring this back to your dog.

Loading your dog’s context…